Abstract:Abstract Super-enhancers (SEs) are large clusters of enhancers that control transcription of genes that define cell identity, and they are frequently acquired by cancer cells to drive key oncogenes. Indeed, the prominent oncogene MYC recurrently acquires SEs in many types of cancer, which may explain its overexpression in a broad array of cancers. Elevated levels of MYC promote transcriptional elongation at promoters of all active genes, thereby amplifying RNA output of the cellular gene expression program. High levels of MYC also lead to increased binding of MYC at enhancers, but the significance of enhancer invasion by MYC is unclear. Here, we propose a model that at tumor cell SEs MYC amplifies the production of enhancer RNAs (eRNAs), which in turn facilitate maintenance of SEs by stabilizing transcription factor and co-factor occupancy. We found that in Burkitt's lymphoma cells SEs depend on high levels of MYC and eRNAs, and that MYC is required for elevated levels of eRNA transcription. We demonstrate that eRNAs directly interact with RNA-binding transcription factors at SEs, and that perturbation of eRNA affects SE signal. Elevated MYC thus contributes to the dynamic formation and maintenance of SEs through amplification of eRNAs. Our results may identify novel RNA targets for new therapies for Burkitt's lymphoma, as well as other cancers. New ways to modulate the immune response may also be revealed by our studies. Citation Format: Yang Eric Guo, Michael Seyffert, Brian Abraham, Xiong Ji, Richard Young. Oncogenic MYC contributes to tumor super-enhancers via eRNA amplification [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr B121.

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

Replication Study: Transcriptional Amplification in Tumor Cells with Elevated C-Myc

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

Abstract B121: Oncogenic MYC Contributes to Tumor Super-Enhancers Via Erna Amplification

MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes

MYC activates transcriptional enhancers to drive cancer progression

Transcriptional regulation by MYC: an emerging new model

The c-Myc target gene network.

Target gene-independent functions of MYC oncoproteins

Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis

Global Mapping Of C-Myc Binding Sites And Target Gene Networks In Human B Cells

A Positive Feedback Loop Between EBP2 and C-Myc Regulates Rdna Transcription, Cell Proliferation, and Tumorigenesis.

MYC Promotes Global Transcription in Part by Controlling P-TEFb Complex Formation Via DNA-binding Independent Inhibition of CDK9 SUMOylation

MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

Registered Report: Transcriptional Amplification in Tumor Cells with Elevated C-Myc

Clinical characterization of MYC family proto-oncogene amplification in solid tumors from Chinese patients.

c-Myc Regulates Transcriptional Pause Release

Target c-Myc to treat pancreatic cancer

MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch

MYC on the Path to Cancer